Samuel Hopkins

Dr. Hopkins has over 30 years of experience in the pharmaceutical industry; the majority of which has been with early stage start-up biotechnology firms. He has held managerial, scientific, and executive leadership positions at the Wellcome Research Laboratories, Trimeris Inc., Parion Sciences, and Scynexis Inc. Currently he directs the clinical research program for Autoimmune Technologies. Dr. Hopkins also provides independent consulting services in drug discovery and development through Valaria Technical Consults LLC.

Throughout his career Dr. Hopkins has participated in multiple aspects of anti-viral drug research including discovery, non-clinical development, and all phases of clinical evaluation. At Trimeris Inc., Dr. Hopkins was responsible for designing and implementing the clinical/regulatory strategy that led to the global approval of Fuzeon® (enfuvirtide) for the treatment of HIV-1 infection. In 2003 The United States Food and Drug Administration recognized the approval of Fuzeon® as a major milestone in HIV-1 drug development. Dr. Hopkins has been a regular presenter at major national and international scientific conferences and has co-authored over 100 abstracts, patents, and peer-reviewed journal articles predominantly in the areas of peptide drug development and anti-viral chemotherapy. This includes his landmark 1998 publication in Nature Medicine, which has been referenced in the peer-reviewed scientific literature over 1,000 times, establishing the HIV-1 gp41 transmembrane protein as a valid target for antiviral chemotherapeutic drug discovery and development.

Dr. Hopkins has participated in private as well as public financings and has raised over $400 million dollars for start-up companies from venture capital sources, NIH grants and contracts, private equity, corporate partnerships, and public equity markets. During his tenure with Trimeris Inc., Dr. Hopkins participated in the company’s Initial Public Offering, secondary offerings, and played an active role in licensing the fusion inhibitor technology platform to Hoffman LaRoche ultimately building the market capitalization of Trimeris Inc., to over $4.0 Billion Dollars.

Dr. Hopkins received his B.A. in Biology cum laude in 1980 from McDaniel College in Westminster, Maryland and his Ph.D. in Biochemistry and Biophysics in 1985 as an A.D. Williams Pre-Doctoral Fellow while attending the Medical College of Virginia in Richmond, Virginia. He completed his post-doctoral training as a Wellcome Foundation Post-Doctoral Fellow at the Wellcome Research Laboratories in Research Triangle Park, North Carolina.